跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CDK9 inhibitors (cancer)
首页
药物
CDK9 inhibitors (cancer)
CDK9 inhibitors (cancer)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS AGENTS FOR TREATMENT OF CANCER
申请人: SUMITOMO PHARMA AMERICA INC
优先权: 2018
CN
EP
US
WO
10 件公开
Method and kits for identifying of CDK9 inhibitors for the treatment of cancer
申请人: MEMORIAL SLOAN KETTERING CANCER CENTER
优先权: 2015
US
CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF
申请人: ALGEN BIOTECHNOLOGIES INC
优先权: 2020
CN
EP
US
6 件公开
A CDK9 INHIBITOR FOR USE IN THE TREATMENT OF CANCER IN A SUBJECT HAVING AN ASXL1 MUTATION
申请人: SELLAS LIFE SCIENCES GROUP INC
优先权: 2024
WO
COMBINATION THERAPY FOR TREATMENT OF CANCER
申请人: INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER
优先权: 2019
EP
US
3 件公开
TARTRATE OF SELECTIVE CDK9 INHIBITOR AND CRYSTAL FORM THEREOF
申请人: CHANGZHOU QIANHONG BIOPHARMA CO LTD
优先权: 2018
CN
EP
US
4 件公开
PI3K-Akt Pathway Inhibitors
申请人: UNIV SOUTH FLORIDA
优先权: 2007
US
Therapeutic compounds
申请人: CHANGZHOU LE SUN PHARMACEUTICALS LTD
优先权: 2012
US
2 件公开
药物
反馈